X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2024
Details:
Under the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize potentially first-in-class treatments for patients with cancer by combining deep expertise in antibody and small molecule development to create precision ADC therapies for patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Prelude Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 01, 2023
Details:
Under the collaboration, AbCellera will discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four and Regeneron has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 20, 2023
Details:
Under the collaboration, AbCellera and Incyte will discover and develop therapeutic antibodies in oncology and Incyte will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 13, 2023
Details:
The collaboration aims for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, leveraging confo's proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations.
Lead Product(s): GPCR Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Confo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2023
Details:
The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent antibodies.
Lead Product(s): Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: RQ Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 22, 2023
Details:
Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease novel antibody-based therapeutic targets, which will be chosen together by both companies.
Lead Product(s): Antibody-based Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rallybio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 01, 2022
Details:
Under the terms of the agreement, Regeneron has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2022
Details:
Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecic engineering technology, and an integrated discovery engine.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Under the terms of deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. Versant and AbCellera partnered in separate multi-target deals to enable three of the firm’s stealth-stage companies with new approaches.
Lead Product(s): Antibody Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
